ACRO, Quintiles, PRA and Theorem talk strategic partnering at DIA 2011

By Gareth Macdonald

- Last updated on GMT

Related tags Contract research organization Pharmacology

The Big Pharma CRO strategic partnering model, its impact on drug development and the contract research sector was a hot topic at DIA 2011. asked representatives from Quintiles Transnational, PRA International and Theorem Clinical Research to share their thoughts on such deals and whether they are good for the sector as a whole.

We also spoke with John Lewis, Vice President of Public Affairs at the Association of Clinical Research Organizations (ACRO) who suggested that more research is needed to assess the efficacy of strategic partnerships.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more